| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3281 |
| Trial ID | NCT05658523 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Randomised Controlled Trial to Assess the Immunogenicity, Safety and Reactogenicity of a Bivalent mRNA Moderna COVID-19 Vaccine or a Protein-based Novavax COVID-19 Vaccine Given as a Fourth Dose in Healthy Adults in Australia |
| Year | 2023 |
| Country | Australia |
| Company sponsor | Murdoch Childrens Research Institute |
| Other ID(s) | 91108 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1273.214 | |||||||
|
|||||||
| Cohort2: Novavax | |||||||
|
|||||||
| Cohort3: no intervention | |||||||
|
|||||||